New drug cocktail aims to Re-Spark immune system against stubborn lung cancer
NCT ID NCT05013450
Summary
This trial is testing the safety and effectiveness of adding two drugs, dupilumab and anakinra, to standard immunotherapy for people with advanced non-small cell lung cancer that has returned or stopped responding to prior treatment. The goal is to see if this three-drug combination can help control the cancer better. The study is for adults whose cancer got worse after they received a type of immunotherapy called a PD-1 or PD-L1 inhibitor.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tisch Cancer Institute, Mount Sinai Hospital
New York, New York, 10003, United States
Conditions
Explore the condition pages connected to this study.